Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma-derived vaccine.
Thirty-one individuals (health care workers) were vaccinated with recombinant hepatitis B vaccine (10 microgram dose) and their immune response (anti-HBs) was compared to that of twenty-five health care workers after vaccination with plasma-derived vaccine (20 microgram dose). Although the seroconversion rate and the percentage of anti-HBs/a antibodies at month 7 were comparable, the geometric mean titre of anti-HBs at month 7 was considerably lower for the recombinant vaccine group (857.4 vs. 6736.5 IU/l). However, vaccinees from the two groups showing seroconversion at month 1 had comparable titres at month 7. Raising the dose of HBsAg in the recombinant vaccine may favourably influence the seroconversion rate at month 1 and thereby the immune response after three injections.
D000328:Adult; D000954:Antigens, Surface / Q000235:genetics / Q000276:immunology; D004274:DNA, Recombinant; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000382:microbiology; D006510:Hepatitis B Antibodies / Q000032:analysis* / Q000276:immunology; D017325:Hepatitis B Vaccines; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000954:Antigens, Surface; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines